A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

Conditions

Advanced Malignancies | Anaplastic Large Cell Lymphoma | Carcinoma, Non-Small-Cell Lung | Diffuse Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors

What is the purpose of this trial?

The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered AP26113, including: the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will assess the preliminary anti-tumor activity of AP26113, both in non-small cell lung cancer (NSCLC) with ALK gene rearrangement (including patients with active brain metastases)or mutated EGFR, and in other cancers with abnormal targets against which AP26113 is active. Approximately 135 to 175 patients will be enrolled.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Ariad Pharmaceuticals
Dates:
September 2011
Last Updated:
August 21, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01449461